厄贝沙坦联合胺碘酮治疗心力衰竭并发室性心律失常临床治疗体会.docVIP

厄贝沙坦联合胺碘酮治疗心力衰竭并发室性心律失常临床治疗体会[摘要] 目的 探讨厄贝沙坦联合胺碘酮治疗慢性心力衰竭（chronic heart failure，CHF）合并室性心律失常（ventricular arrhythmia，VA）的安全性及有效性。 方法 选择2010年3～5月在本院收治的138例CHF合并VA的患者，随机分成观察组70例和对照组68例，两组患者均给予强心、利尿、扩血管等常规治疗，并给予胺碘酮，观察组在此基础上加用厄贝沙坦，两组的用药时间均为10周，观察比较两组的治疗效果。 结果 两组患者治疗后，观察组的心功能疗效总有效率和VA疗效总有效率均明显高于对照组，两组比较差异有统计学意义（P ＜ 0.05）。 结论 厄贝沙坦联合胺碘酮治疗CHF合并VA能有效改善心功能、控制心律失常，是一种安全有效的治疗手段。 [关键词] 厄贝沙坦；胺碘酮；心力衰竭；心律失常 [中图分类号] R972 [文献标识码] A [文章编号] 1674-4721（2012）07（b）-0081-02 Clinical treatment experience of irbesartan joint amiodarone in treatment of heart failure and ventricular arrhythmia WU Zongwen FANG Yunyong Medicine Department, Maternal and Child Health Hospital of Dongguan City in Guangdong Province, Dongguan 523000, China [Abstract] Objective To investigate the safety and effectiveness of irbesartan joint amiodarone treatment for heart failure and ventricular arrhythmia. Methods One hundred and thirty-eight patients treated in our hospital from March to May 2010 were randomly divided into the observation group 70 cases and the control group 68 cases, all the patients received conventional therapy with strong heart, diuresis, enlarge blood vessels, and were given the amiodarone, the observation group were added with irbesartan on this basis, the two groups of drug use time were for ten weeks, the efficacy of two groups were observed and compared. Results After treatment in both groups, the total effective rate of cardiac function curative effect and VA curative effect in the therapeutic group was better than those of the control group, there was significant difference between them (P 0.05). Conclusion Irbesartan joint amiodarone treatment of CHF merger VA can effectively improve heart function and control arrhythmia, it is a safe and effective treatment. [Key words] Irbesartan; Amiodarone; Heart failure; Arrhythmia 慢性心力衰竭（chronic heart failure，CHF）是一种复杂的临床综合征，为各种心脏病的终末阶段[1]，常合并各种心律失常，尤以室性心律失常（ventricular arrhythmia，VA）最常见[2]。如不及时治疗，会导致病情恶化发生猝死。目前许多抗心律失常药物均有不同程度副作用，且极易导